

Resource Summary Report

Generated by [dkNET](#) on Aug 1, 2026

EMT6

RRID:CVCL_1923

Type: Cell Line

Proper Citation

CLS Cat# 305159, RRID:CVCL_1923

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1923

Proper Citation: CLS Cat# 305159, RRID:CVCL_1923

Description: Cell line EMT6 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Malignant neoplasms of the mouse mammary gland

Defining Citation: [PMID:4647494](#), [PMID:31220119](#)

Comments: Characteristics: Established from the transplantable mammary tumour KHJJ.

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: EMT6

Synonyms: EMT-6, Experimental Mammary Tumour-6

Cross References: BTO:BTO_0003329, CLO:CLO_0002926, ATCC:CRL-2755, BioGRID_ORCS_Cell_line:1262, BioSample:SAMN11397651, ChEMBL-Cells:ChEMBL3307584, ChEMBL-Targets:ChEMBL614294, CLS:305159, NCI-DTP:EMT-6, PubChem_Cell_line:CVCL_1923, Wikidata:Q54832294

ID: CVCL_1923

Vendor: CLS

Catalog Number: 305159

Record Creation Time: 20220923T070658+0000

Record Last Update: 20260726T000732+0000

Ratings and Alerts

No rating or validation information has been found for EMT6.

No alerts have been found for EMT6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 255 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhou TH, et al. (2025) Overexpression of RUNX2 promotes breast cancer multi-organ metastasis through stabilizing c-Myc. *Cell death & disease*, 16(1), 696.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.

Mei W, et al. (2025) A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor. *Cell*, 188(2), 371.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. *Cell*, 188(26), 7591.

Zhou X, et al. (2025) Potentiating anti-tumor immunity by re-engaging immune synapse molecules. *Cell reports. Medicine*, 6(3), 101975.

Liu Y, et al. (2025) Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer. *Cell reports. Medicine*, 6(1), 101915.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. *Cell reports. Medicine*, 102515.

Khan KA, et al. (2025) Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade. *Cell reports. Medicine*, 6(9), 102322.

Osaki M, et al. (2025) Soluble CTLA-4 regulates immune homeostasis and promotes resolution of inflammation by suppressing type 1 but allowing type 2 immunity. *Immunity*, 58(4), 889.

Yu L, et al. (2025) Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. *Immunity*, 58(4), 909.

Cho NW, et al. (2025) T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNF? *Inflammation. Cancer immunology research*, 13(2), 229.

Cui Q, et al. (2025) MIF-ACKR3 causes irreversible fat loss by impairing adipogenesis in cancer cachexia. *Cell metabolism*, 37(4), 954.

Schwarz E, et al. (2025) Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer. *Cancer immunology research*, 13(4), 560.

Taylor D, et al. (2025) Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer. *Cell reports. Medicine*, 6(11), 102451.

Chariou PL, et al. (2024) Generation of murine tumor models refractory to ?PD-1/-L1 therapies due to defects in antigen processing/presentation or IFN? signaling using CRISPR/Cas9. *PloS one*, 19(3), e0287733.

Dheeraj A, et al. (2024) Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy. *Cell reports. Medicine*, 5(5), 101552.

Fontana P, et al. (2024) Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity. *Cell*, 187(22), 6165.

Kumar S, et al. (2024) Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. *Cell reports. Medicine*, 5(9), 101698.

Benguigui M, et al. (2024) Interferon-stimulated neutrophils as a predictor of immunotherapy response. *Cancer cell*, 42(2), 253.

Ma Y, et al. (2024) Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma. *Cell reports. Medicine*, 5(2), 101414.